Solna on 2 December 2021 – In accordance with the instruction for the Nomination Committee, which was adopted at Oasmia Pharmaceutical AB’s (”Oasmia”) Annual General Meeting on 27 May 2021, it is hereby announced that the Nomination Committee for the 2022 Annual General Meeting has been appointed, based on the ownership structure as per 30 September 2021.
The Nomination Committee for the 2022 Annual General Meeting comprises the following members:
- Per Arwidsson, appointed by Arwidsro Investment AB,
- Håkan Lagerberg, appointed by Mastan AB, and
- Anders Härfstrand, Chairman of the Board of Oasmia.
Per Arwidsson has been appointed Chairman of the Nomination Committee.
Oasmia’s Annual General Meeting will be held on 25 May 2022.
Shareholders who wish to submit proposals to the Nomination Committee for the 2022 Annual General Meeting may send them by e-mail to nomination@oasmia.com. In order for the Nomination Committee to be able to consider submitted proposals in a constructive manner, these should be submitted well in advance of the Annual General Meeting.
For more information:
Anders Härfstrand, Chairman of the Board of Oasmia
Phone: 018-50 54 40
E-mail: IR@oasmia.com
About Oasmia Pharmaceutical AB
Oasmia is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. It has a growing pipeline of clinical-stage assets targeting late-stage cancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancer patients through a partnership with Elevar Therapeutics, Inc. Development programs include Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxel micellar, in development for advanced prostate cancer. Oasmia has proprietary drug delivery technology designed to improve solubility, efficacy and safety. Oasmia’s shares are traded on Nasdaq Stockholm (OASM). To find out more about Oasmia please visit www.oasmia.com.